BENDEKA

Peak

bendamustine hydrochloride

NDAINTRAVENOUSSOLUTION
Approved
Dec 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9

Mechanism of Action

purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways.…

Clinical Trials (5)

NCT02240719Phase 1Completed

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

Started Oct 2014
20 enrolled
Recurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Grade 1 Follicular Lymphoma+5 more
NCT01739491N/AWithdrawn

A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia

Started Oct 2014
0
Chronic Lymphocytic Leukemia
NCT01900509Phase 1Completed

Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies

Started Aug 2013
16 enrolled
Hodgkin LymphomaNon-Hodgkin LymphomaAcute Leukemia
NCT04569838Phase 2Completed

A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection

Started May 2012
NCT01429025Phase 1Completed

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

Started May 2012
26 enrolled
Refractory/Relapsed Indolent Non-Hodgkin Lymphoma

Loss of Exclusivity

LOE Date
Mar 15, 2033
85 months away
Patent Expiry
Mar 15, 2033

Patent Records (5)

Patent #ExpiryTypeUse Code
8791270
Jan 12, 2026Expired
Product
U-1790
9265831
Jan 28, 2031
Product
9572796
Jan 28, 2031
Product
U-1971
9572797
Jan 28, 2031
U-1972
12138248
Jan 28, 2031
Product